Bronchiolitis Clinical Trials
Here are the 6 most popular medical studies for bronchiolitis
Janus Kinase Inhibitor
Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant
This trial is testing whether a new combination of drugs can help treat a common and serious side effect of a stem cell transplant that often leads to long-term problems or even death.
Neutrophil Elastase Inhibitor
Alvelestat for Bronchiolitis Obliterans Syndrome
This trial is testing a new drug, alvelestat (MPH966), to see if it's safe and effective in treating bronchiolitis obliterans syndrome (BOS). BOS is a complication people can experience after hematopoietic stem cell transplant.
Procedure
Oxygen delivery for Bronchiolitis
Bronchiolitis is a common cold weather seasonal respiratory illness affecting infants and children. Multiple supportive therapies have been tried in infants with bronchiolitis including albuterol, racemic epinephrine, hypertonic saline nebulization, but to date supportive therapy with oxygen is the only proven therapy to decrease respiratory distress in infants with bronchiolitis, with hypertonic saline showing a borderline statistically significant improvement. This prospective, randomized study will compare CSS and PEWS scores on infants who receive oxygen by standard flow nasal cannula and to those who receive oxygen via Humidified High-Flow Nasal Cannula (HHFNC). The results will help determine if infants with viral bronchiolitis who receive humidified high flow nasal cannula oxygen therapy have improved Clinical Severity Score (CSS) and Pediatric Early Warning System (PEWS) scores and ultimately decreased lengths of admissions when compared to patients treated with nasal cannula oxygen therapy with/without bronchodilator therapy. Hypothesis Heated Humidified High-flow Nasal Cannula Delivery of Oxygen decreases respiratory distress as measured by pediatric CSS and PEWS when compared with routine nasal cannula oxygen delivery in infants with bronchiolitis.
Procedure
Positive Airway Pressure nebulization +1 More for Bronchiolitis
Hypothesis: That administration of nebulized therapy for bronchiolitis when using positive airway pressure is superior to standard mask ventilation in reducing hospital admissions. Bronchiolitis is a lower respiratory tract infection (LRTI) syndrome caused by a variety of different viruses. It is the most common LRTI in children under 24 months old. Multiple studies have documented variation in treatment, hospitalization rates, and length of hospital stay for bronchiolitis, suggesting a lack of consensus and an opportunity to improve care for this common disorder. Research to determine optimal delivery methods of respiratory medications that may augment oxygenation by decreasing atelectasis (Lung cell collapse) and increasing oxygen saturation have not been done. Currently bronchodilators are delivered through a passive process, inhaled as they are nebulized (made from liquid into gas) into a face mask. This study will evaluate whether using a newly developed positive pressure nebulization device that uses pressure to expand lung cells and, hypothetically, deliver the medication better, improves oxygenation by reducing atelectasis (lung cell collapse) to decrease hospitalization in infants with moderate to severe bronchiolitis. Positive pressure nebulization is a relatively new adaptation of a previously existing modality, and is already currently in use here at PCH.
Popular filter options for bronchiolitis trials
Bronchiolitis Obliterans Clinical Trials
View 7 Bronchiolitis Obliterans medical studies.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
BO Clinical Trials
View 7 BO medical studies.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Phase 3 Bronchiolitis Clinical Trials
View 26 phase 3 bronchiolitis medical studies.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Immunomodulator
ARINA-1 for Bronchiolitis Obliterans Syndrome
This trial compares the effectiveness of a new drug to the existing standard of care for lung transplant recipients to see if it can improve quality of life and prevent or delay the need for additional treatment.
Bronchiolitis Clinical Trials With No Placebo
View 26 bronchiolitis medical studies that do not have a placebo group.
Procedure
Standard Non-Invasive Mechanical Servo Ventilation +1 More for Bronchiolitis
This trial aims to find out if using a special mode of non-invasive ventilation called Neurally-Adjusted Ventilatory Assistance (NAVA) can improve comfort and reduce the need for more intensive treatment
CDS + HHFNC Weaning for Bronchiolitis
This trial aims to improve recovery from common pediatric respiratory illnesses, reduce costs, and show UPMC Children's Hospital's capabilities in pediatric healthcare. It will examine using CDS to improve adherence to standardized guidelines and outcomes.
Behavioral Intervention
Clinical Pathway Intervention for Pediatric Respiratory Conditions
This trial will test whether a multi-condition clinical pathway intervention can help community hospitals improve care for children with asthma, pneumonia, or bronchiolitis.
Evidence-Based Care Strategy for Bronchiolitis
This trial will help healthcare professionals learn how to better provide care that is evidence-based and in line with guidelines, in order to improve patient outcomes and decrease the amount of money spent on over-testing and over-treatment.
View More Bronchiolitis Trials
See another 5 medical studies focused on bronchiolitis.
Frequently Asked Questions
Introduction to bronchiolitis
What are the top hospitals conducting bronchiolitis research?
Bronchiolitis, a common respiratory infection affecting infants and young children, has prompted several leading hospitals to undertake clinical trials in search of improved treatments. Among these institutions is the esteemed Cleveland Clinic in Cleveland, which currently has six active bronchiolitis trials underway, building upon its earlier accomplishment of eight completed studies since recording its first trial in 2008. Meanwhile, Baylor University Medical Center in Dallas is making noteworthy strides with four ongoing bronchiolitis trials, marking their involvement and commitment since initiating their initial trial back in 2015.
In Houston's medical landscape lies Houston Methodist Hospital—a facility that recognizes the importance of combating bronchiolitis through research. This hospital currently conducts four active clinical trials for this condition while maintaining an equal number of previously held investigations. Their journey began just two years ago with their inaugural bronchiolitis trial in 2019. Similarly dedicated to advancing knowledge about this troubling illness is Banner Health located in Phoenix; they too are actively involved with three current bronchiolitis studies and have contributed to our understanding by undertaking three previous investigations starting from 2019 as well.
Last but not least on this list stands Stanford University Hospital situated amidst Palo Alto's renowned medical community. Despite having only started recording data on bronchiolitis clinical trials a couple of years ago—just like Hospital #3 and #4—they are already conducting three active studies for the condition while having accomplished an equivalent number thus far.
Research conducted at these top-tier hospitals signifies significant progress towards improving outcomes for those affected by bronchiolitis, particularly vulnerable infants and children who bear the brunt of this respiratory infection's impact. The dedication displayed by these institutions underscores their commitment to pioneering innovative treatments and potentially revolutionizing care for countless young patients worldwide facing this challenging condition.
Which are the best cities for bronchiolitis clinical trials?
When it comes to bronchiolitis clinical trials, several cities emerge as key hubs for research. Philadelphia, Pennsylvania leads the way with 11 active trials investigating treatments like itacitinib and Liposomal Cyclosporine A. Houston, Texas and Boston, Massachusetts closely follow with 9 ongoing studies each focused on interventions such as Audit & Feedback (unit level) and Cohort A: Belumosudil + Standard of Care Medications. Columbus, Ohio and Dallas, Texas also contribute to the advancement of bronchiolitis care through their ongoing trials exploring various treatments including ARINA-1 plus standard of care. These cities provide individuals affected by bronchiolitis access to cutting-edge clinical trials that pave the way for improved treatment options in the future.
Which are the top treatments for bronchiolitis being explored in clinical trials?
Exciting advancements are underway in the exploration of treatments for bronchiolitis, with two standout contenders leading the way in current clinical trials. Liposomal Cyclosporine A, introduced in 2019, has shown promise and is currently being tested in two ongoing trials specifically for bronchiolitis. Similarly, Itacitinib, making its debut in 2020, is also being investigated through two active trials dedicated to this respiratory condition. As researchers delve deeper into these potential therapies and gather valuable data from their studies, there is hope that new avenues for managing bronchiolitis will soon be within reach.
What are the most recent clinical trials for bronchiolitis?
Recent clinical trials for bronchiolitis have shown promising developments in the field of treatment. Sirolimus, a drug currently undergoing Phase 2 trials, holds potential as a therapeutic option for this respiratory condition. In addition, the ARINA-1 trial is evaluating the efficacy of ARINA-1 combined with standard care in Phase 3 studies. Another notable study investigated Ruxolitinib's effectiveness and safety in treating bronchiolitis during its Phase 2 stage. Additionally, magnesium sulfate has undergone both Phase 2 and Phase 3 trials to assess its impact on bronchiolitis management. Lastly, Itacitinib is being evaluated through a Phase 1 trial to determine its feasibility as a treatment option for bronchiolitis patients. These ongoing investigations bring hope for improved outcomes and better quality of life for individuals affected by this condition.
What bronchiolitis clinical trials were recently completed?
Stanford University recently completed a clinical trial investigating the potential of Pirfenidone 267 MG [Esbriet] in treating bronchiolitis. This significant milestone marks an important step towards improved treatments for this respiratory condition.